Esomeprazole
Esomeprazole Zentiva contains the active substance esomeprazole. It belongs to a group of medicines called ‘proton pump inhibitors’. These medicines reduce the amount of acid produced in the stomach.
Esomeprazole Zentiva is used for short-term treatment of certain diseases when the patient is not able to take oral medicines. This medicine is used for the treatment of the following diseases:
Adults
Children and Adolescents Aged 1 to 18 Years
Esomeprazole Zentiva must not be used in patients who have any of the above conditions. If you are not sure, talk to your doctor or nurse before using Esomeprazole Zentiva.
Before starting treatment with Esomeprazole Zentiva, tell your doctor if:
Esomeprazole may mask the symptoms of other diseases. You should tell your doctor immediately if you notice any of the following symptoms before or while using Esomeprazole Zentiva:
Taking a proton pump inhibitor like esomeprazole, especially over a period of more than one year, may slightly increase the risk of hip, wrist, or spine fractures. You should tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).
If you get a rash on your skin, especially in areas exposed to the sun, you should contact your doctor as soon as possible, as you may need to stop your treatment with esomeprazole. Also, remember to mention any other side effects like joint pain.
Severe skin reactions have occurred in patients taking esomeprazole (see also section 4). These can include blistering of the skin and mucous membranes (Stevens-Johnson syndrome), and a condition known as toxic epidermal necrolysis.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This includes medicines obtained without a prescription. This is because esomeprazole may affect the way some medicines work and some medicines may affect the way esomeprazole works.
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Your doctor will decide whether you can take Esomeprazole Zentiva during this time.
It is not known if esomeprazole passes into breast milk. Therefore, you should not take Esomeprazole Zentiva if you are breast-feeding.
Esomeprazole Zentiva is unlikely to affect your ability to drive or use machines. However, side effects such as dizziness and blurred vision may occur (see section 4). If affected, you should not drive or use machines.
Esomeprazole can be given to children and adolescents aged 1 to 18 years and adults, including the elderly.
Adults
Children and Adolescents Aged 1 to 18 Years
If you think you have been given too much Esomeprazole Zentiva, tell your doctor immediately.
Like all medicines, Esomeprazole Zentiva can cause side effects, although not everybody gets them.
Other side effects include:
Common (affects less than 1 in 10 people):
Uncommon (affects less than 1 in 100 people):
Rare (affects less than 1 in 1,000 people):
Very Rare (affects less than 1 in 10,000 people):
Frequency Not Known: frequency cannot be estimated from the available data.
In very rare cases, esomeprazole may affect the white blood cells, leading to immune deficiency. If you have an infection with symptoms such as fever and serious deterioration of your general condition, or fever with symptoms of a local infection such as sore throat/pharynx/mouth or urinary problems, you must consult your doctor as soon as possible so that a lack of white blood cells (agranulocytosis) can be ruled out by a blood test. It is important to inform your doctor about your medicine.
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in the website. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Your doctor or hospital pharmacist are responsible for the proper storage, use, and disposal of Esomeprazole Zentiva.
Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The expiry date refers to the last day of that month.
Do not store above 25°C.
Store in the original package in order to protect from light. Vials may be stored and exposed to light inside the room for up to 24 hours outside of the carton. Do not store in a refrigerator.
Chemical and physical in-use stability has been demonstrated for 12 hours at 30°C.
From a microbiological point of view, unless the method of reconstitution precludes the risk of microbial contamination, the product should be used immediately.
If not used immediately, in-use storage times and conditions are the responsibility of the user.
Do not use the solution if you notice any signs of deterioration.
The active substance is esomeprazole in the form of esomeprazole sodium.
Each vial of powder for solution for injection/infusion contains 42.5 mg esomeprazole sodium, equivalent to 40 mg esomeprazole.
The other ingredients are disodium edetate and sodium hydroxide (for pH adjustment).
Each vial contains less than 1 mmol (23 mg) sodium, i.e. essentially sodium-free.
Esomeprazole Zentiva, 40 mg, powder for solution for injection/infusion is a white to off-white porous disk or powder. Before administration, it is reconstituted to form a solution.
Esomeprazole Zentiva is provided in a vial made of colorless glass type I, with a capacity of 5 mL, closed with a dark grey butyl rubber stopper and an aluminum flip-off seal, in a cardboard box.
Esomeprazole Zentiva is available in packs containing 1, 10, or 50 vials.
Not all pack sizes may be marketed.
Zentiva, k.s.
U kabelovny 130
Dolní Měcholupy
102 37 Prague 10
Czech Republic
Tillomed Malta Limited,
Malta Life Sciences Park,
LS2.01.06 Industrial Estate,
San Gwann, SGN 3000, Malta
Germany
Esomeprazole Tillomed 40 mg Powder for Solution for Injection/Infusion
Italy
Esomeprazole Tillomed
France
ESOMEPRAZOLE TILLOMED 40 mg, powder for solution for injection/infusion
Poland
Esomeprazole Zentiva
Austria
Esomeprazole Tillomed 40 mg Powder for Solution for Injection/Infusion
Netherlands
Esomeprazole Tillomed 40 mg powder for solution for injection/infusion
Ireland
Esomeprazole Tillomed 40 mg powder for solution for injection/infusion
Zentiva Polska Sp. z o.o.
ul. Bonifraterska 17
00-203 Warsaw
tel.: +48 22 375 92 00
Date of Last Revision of the Leaflet:January 2025
Esomeprazole Zentiva, 40 mg, powder for solution for injection/infusion contains 40 mg esomeprazole in the form of esomeprazole sodium. Each vial contains disodium edetate and sodium hydroxide (<1 mmol sodium).
The vials are for single use only. If the full reconstituted contents of the vial are not used for a single dose, any unused solution should be discarded.
For further information on dosing and storage conditions, see sections 3 and 5 respectively.
In order to reconstitute the solution, remove the plastic color-coded cap from the top of the vial of Esomeprazole Zentiva, 40 mg, powder for solution for injection/infusion and insert the needle through the center of the rubber stopper and inject the recommended amount of solvent. The reconstituted solution for injection/infusion should be clear and colorless to very pale yellow. Before administration, inspect the solution visually for particulate matter and discoloration. Only clear solutions should be used.
Preparation of the Solution for Injection:
Dose of 40 mg for Injection
To prepare the reconstituted solution of esomeprazole 8 mg/mL: add 5 mL of 0.9% sodium chloride solution for injection to the vial containing 40 mg esomeprazole.
The reconstituted solution for injection should be administered intravenously over a period of at least 3 minutes.
For further information on dosing, see SmPC section 4.2.
Preparation of the Solution for Infusion:
Dose of 40 mg for Infusion (400 μg/mL or 0.4 mg/mL)
Dissolve the contents of one vial containing 40 mg esomeprazole in up to 100 mL 0.9% sodium chloride solution for injection.
Dose of 80 mg for Infusion (800 μg/mL or 0.8 mg/mL)
Dissolve the contents of two vials containing 40 mg esomeprazole in up to 100 mL 0.9% sodium chloride solution for injection.
Any unused product or waste material should be disposed of in accordance with local requirements.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.